RBC Reiterates Outperform Rating on Eli Lilly, Keeps $1,500 Target
RBC Capital reiterated its Outperform rating on Eli Lilly and a $1,500 price target. The target implies 27.2% upside from the Oct. 9 close of $1,179.27.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.